Weekend Blog Watch - TheStreet

Billions are spent treating Parkinson's Disease each year. Not only would a cure be of immense benefit to society, but it would make the company involved billions.

Here are the public companies

closest to a cure/treatment.

Remember Erin Brockovich? Well, now she's an executive at a

micro-cap public company

.

Time to analyze the

52-week-low list

where often the bargains can be found.

This is the best analysis of

brand value I've seen

. I now finally understand what it means (or should mean) when someone says

Google

(GOOG) - Get Report

has a more valuable brand than

Coca Cola

(KO) - Get Report

.

Jeremy Siegel shares some

Buffett wisdom

.

Dealbreaker breaks down

AT&T

(T) - Get Report

CEO Whitacre's pay

.

Here are Stockpickr's

latest activist situations

, where hedge funds are clamoring to unlock value in deep-value situations. Today's list includes

Nautilus

(NLS) - Get Report

and

Flow International

(FLOW) - Get Report

, as well as homebuilder

Beazer Homes

(BZH) - Get Report

.

It was

65 years ago today

.

Top 10 Small-Cap Value Plays

.

The options tell the whole story. Counting down an

FDA decision

on

Dendreon's

(DNDN)

Provenge.

Finally, can

XM Satellite Radio

( XMSR) and

Sirius

(SIRI) - Get Report

hit bottom?

What's the sum of the parts if

General Electric

(GE) - Get Report

breaks up

.

Notable Calls thinks

MEMC Electronic Materials

(WFR)

might be

a bounce play here

.

The Stockmasters have some thoughts about what you should do with your money if you believe in "

sell in May and go away

."

Hmm, is this even a possibility? Can

Google buy NBC

?

And if you missed it,

Cramer's Portfolios of the week

.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider Nautilus, Flow International and Dendreon to be small-cap stocks. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

At the time of publication, Altucher and/or his fund had no positions in the stocks mentioned, although positions may change at any time.

James Altucher is a managing partner at Formula Capital, an alternative asset management firm that runs several quantitative-based hedge funds as well as a fund of hedge funds. He is also the author of

Trade Like a Hedge Fund

and

Trade Like Warren Buffett

. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Altucher appreciates your feedback;

click here

to send him an email.

TheStreet.com has a revenue-sharing relationship with Trader's Library under which it receives a portion of the revenue from purchases by customers directed there from TheStreet.com.